Nicholas Paolella

US Patent:

42207924, Sep 2, 1980

Filed:

Jan 25, 1979

Appl. No.:

6/006462

Inventors:

Paul L. Anderson - Dover NJ
Nicholas A. Paolella - Livingston NJ

Assignee:

Sandoz, Inc. - E. Hanover NJ

International Classification:

C07D23114

US Classification:

548378

Abstract:

Anti-diabetic agents of the formula: ##STR1## wherein R is CHO or COOR. sub. 1, where R. sub. 1 is hydrogen or C. sub. 1-6 alkyl, R. sub. o is C. sub. 1-4 alkyl, C. sub. 1-4 alkoxy, bromo, chloro, fluoro, trifluoromethyl, nitro or ##STR2## where R. sub. 2 is hydrogen or C. sub. 1-4 alkyl, and n is 0 or 1, and the non-toxic, pharmaceutically acceptable salts thereof.

US Patent:

43594743, Nov 16, 1982

Filed:

Nov 28, 1980

Appl. No.:

6/211361

Inventors:

Paul L. Anderson - Dover NJ
Nicholas A. Paolella - Livingston NJ

Assignee:

Sandoz, Inc. - East Hanover NJ

International Classification:

A61K 31415

US Classification:

424273P

Abstract:

The invention discloses certain 1-phenyl-pyrazole derivatives having pharmacological activity in animals and useful as glucagon inhibiting agents. Nearly all of the compounds of this invention are prepared by cyclization of a phenyl hydrazine compound with a 1,1,3,3-tetra-C. sub. 1-4 -alkoxy-propane compound.

US Patent:

49391593, Jul 3, 1990

Filed:

Mar 8, 1989

Appl. No.:

7/320664

Inventors:

Paul L. Anderson - Randolph NJ
Faizulla G. Kathawala - Mountain Lakes NJ
Nicholas A. Paolella - Livingston NJ
Sompong Wattanasin - Hopatcong NJ

Assignee:

Sandoz Pharm. Corp. - E. Hanover NJ

International Classification:

A61K 31435
C07D47104

US Classification:

514300

Abstract:

Compounds of the formula I: ##STR1## wherein X is the residue of an unsubstituted 6-membered aromatic ring having 3 carbon atoms and one nitrogen atom; R. sup. 1 is C. sub. 1-6 primary alkyl (free of asymmetric carbon atoms), or isopropyl; R. sup. 2 is substituted or unsubstituted phenyl, primary or secondary C. sub. 1-6 alkyl (free of asymmetric carbons), C. sub. 3-6 cycloalkyl or phenalkyl as defined in the Specification ##STR2## in which R. sup. 8 is hydrogen, R. sup. 9 or M, wherein R. sup. 9 is a physiologically acceptable and hydrolyzable ester group, and M is a pharmaceutically acceptable cation; are obtained by multi-step processes and are useful as cholesterol biosynthesis inhibitors. 3.